Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 11, Number 6—June 2005


Emergence and Spread of Streptococcus pneumoniae with erm(B) and mef(A) Resistance

David J. Farrell*Comments to Author , Stephen G. Jenkins†, Steven D. Brown‡, Manish Patel§, Bruce S. Lavin§, and Keith P. Klugman¶#
Author affiliations: *G.R. Micro Ltd, London, United Kingdom; †Mount Sinai School of Medicine, New York, New York, USA; ‡Clinical Microbiology Institute, Wilsonville, Oregon, USA; §sanofi-aventis, Bridgewater, New Jersey, USA; ¶Emory University, Atlanta, Georgia, USA; #University of the Witwatersrand, Johannesburg, South Africa

Main Article

Table 4

Susceptibility to various antibacterial drugs among Streptococcus pneumoniae isolates collected from years 1–3 of the PROTEKT US study that had both erm(B) and mef(A) macrolide resistance genes (n = 1,159)

Drug % susceptibility*
Susceptible Intermediate Resistant
Amoxicillin–clavulanate† 40.6 22.0 37.4
Azithromycin 0 0.1 99.9
Cefuroxime 5.7 1.7 92.6
Clarithromycin 0 0 100
Co-trimoxazole 3.4 1.2 95.4
Erythromycin 0 0 100
Levofloxacin 98.6 0 1.4
Linezolid 99.8 0 0.2
Penicillin 1.5 6.7 91.8
Telithromycin 99.0 0.9 0.1
Tetracycline 2.7 0.7 96.6

*Susceptibility was defined according to Clinical and Laboratory Standards Institute interpretive criteria (25).
†Amoxicillin alone was not tested; however, susceptibility can be extrapolated from the amoxicillin-clavulanate results.

Main Article

Top of Page The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO